ANIP

Over the past six months, ANI Pharmaceuticals' stock price, which was $72.65 per share as of September 30, 2026, experienced a 19.43% decline over the past year. In May 2026, Q1 2026 earnings showed strong adjusted EPS and revenues exceeding estimates, and raised full-year guidance, but the stock fell over 2% due to slightly softer Cortrophin Gel sales impacted by seasonality and weather. In August 2026, Q2 2026 results topped revenue expectations with sales up 25.9% year-on-year to $266 million and adjusted EPS of $2.21, beating analyst estimates, yet the stock declined by 5.3% due to full-year revenue guidance coming in 1% below analysts' estimates and a cut in Cortrophin guidance. On September 23, 2026, Oppenheimer initiated coverage with a 'Perform' recommendation, and ANI Pharmaceuticals announced FDA approval for its Abbreviated New Drug Application for Everolimus Tablets for Oral Suspension, a generic version of Afinitor Disperz.